In comparison with the sorafenib-naïve HCC cells, the sorafenib-resistant HCC cells exhibited a more mesenchymal cell morphology (Figure 1A), had a higher half-maximal inhibitory concentration (IC50) value under sorafenib treatment (Figure 1B), and had significantly higher IGF-1R protein expression level (Figure 1C). This evidence concerns the gene IGF1R and hepatocellular carcinoma.